Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
Inv. presentation
Credit agrmnt [a]
Acq. announced
Director departure
Appointed director
Employment agrmnt
AMAG PHARMACEUTICALS, INC. (AMAG) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2020 8-K Quarterly results
10/01/2020 8-K Quarterly results
08/17/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
07/27/2020 8-K Quarterly results
07/23/2020 8-K Quarterly results
06/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "###"
06/04/2020 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/11/2020 8-K Quarterly results
04/28/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement This Employment Agreement is entered into by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 , and Scott Myers of [***] . WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on April 28, 2020, , subject to a satisfactory background check and final approval by the Company’s Board of Directors on the terms contained herein. NOW THEREFORE, in consideration of the premises and mutual agreements hereinafter set forth, and intending to be legally bound hereby, the parties hereto agree as follows: 1.Position; Duties. Position. You shall serve as the President and Chief Executive Officer of the Company. In addition, the Company shall cause you...",
"AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Officer"
04/16/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "###"
03/04/2020 8-K Quarterly results
01/09/2020 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update Initiating CEO transition plan Divesting Intrarosa® and Vyleesi® 2020 financial guidance reflects reduction in annual operating expenses of more than $100M and a return to positive adjusted EBITDA",
"AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020"
12/03/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/01/2019 8-K Quarterly results
10/30/2019 8-K Quarterly results
10/08/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
08/07/2019 8-K Investor presentation, Quarterly results
Docs: "AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Promoted products achieved sequential and year-over-year revenue and market share growth 2019 financial guidance lowered: exiting Makena intramuscular market and removing milestone revenue Vyleesi on-track for national launch in September Conference call scheduled for 8:00 a.m. ET today",
"Copy of AMAG Pharmaceuticals, Inc.’s presentation slides"
06/21/2019 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VYLEESI™ FOR ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER IN PREMENOPAUSAL WOMEN"
05/22/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Analyst Day Presentation Materials"
05/17/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2019 8-K Quarterly results
Docs: "AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Achieved record Feraheme revenue growth and more than 50% market share for Makena auto-injector Completed integration of Perosphere Pharmaceuticals Inc. and progressed ciraparantag clinical program Reaffirms 2019 financial guidance Conference call scheduled for 8:00 a.m. ET today",
"Copy of AMAG Pharmaceuticals, Inc.’s presentation slides"
04/12/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMAG PHARMACEUTICALS APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS"
04/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AMAG PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM THE PROLONG TRIAL EVALUATING MAKENA ®"
02/07/2019 8-K Quarterly results
01/17/2019 8-K Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AMAG PHARMACEUTICALS COMPLETES ACQUISITION OF PEROSPHERE PHARMACEUTICALS"
01/07/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial Guidance Achieves 2018 revenue of between $471 million and $476 million, including approximately 28% growth in Feraheme® sales Acquisition of two development-stage assets creates a strong and diversified portfolio, leveraging therapeutic area expertise",
"Copy of AMAG Pharmaceuticals, Inc.’s presentation slides"
12/13/2018 8-K Investor presentation
Docs: "Agreement and Plan of Merger, by and among AMAG Pharmaceuticals, Inc., Magellan Merger Sub, Inc., Perosphere Pharmaceuticals Inc. and Bryan E. Laulicht, as the representative of the Perosphere Equityholders",
"AMAG PHARMACEUTICALS ENTERS INTO DEFINITIVE MERGER AGREEMENT TO ACQUIRE PEROSPHERE PHARMACEUTICALS",
"[LOGO] This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG's belief that ciraparantag will bolster its pipeline of durable growth assets; AMAG's beliefs regarding the clinical efficacy, safety data and population market of ciraparantag and its anticipated regulatory timeline; AMAG's belief that the acquisition structure mitigates risk and maximizes corporate flexibility; the timing and value of future milestone payments; expectations regarding the impact of the transaction on AMAG's preliminary view of its 2019 adjusted EBITDA; expectations regarding the U.S. and world-wide marke..."
11/13/2018 8-K Regulation FD Disclosure
11/02/2018 8-K Asset disposition
Docs: "Earnings call transcript"
11/01/2018 8-K Quarterly results
Docs: "AMAG PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the company's focus on delivering innovative therapies that address unmet medical needs Conference call scheduled for 8:00 a.m. ET today",
"Copy of AMAG Pharmaceuticals, Inc.’s presentation slides"
09/26/2018 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy